Global RWE Oncology Market Research Report 2022
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "RWE Oncology Market by Component, Application, End User - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029.
After a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.
The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.
Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.
Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
In 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.
Market Insights
Drivers
Growing Burden of Cancer
Rising Focus Towards Personalized Healthcare
Delays in Drug Development and the Subsequent Increase in Development Costs
Shift Towards Value-based Care
Rapidly Growing Big Data in Healthcare
Restraints
Reluctance to Rely on Real-world Studies
Opportunities
Emerging Economies
Rising Focus on End-to-end RWE Services
Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE
Challenges
Lack of Standardized Methodologies to Develop RWE
Impact Assessment of COVID-19
Key Market Trends
Growing Adoption of RWE in Drug Development and Commercialization
Rising Number of Consolidations
Improved Patient Outcomes and value Creation from Real-world Evidence
Company Profiles
IQVIA Holdings Inc.
ICON plc
PPD Inc.
SYNEOS HEALTH Inc.
CLARIVATE PLC
Medpace Holdings Inc.
Symphony Innovation LLC
Clinigen Group plc
Cognizant Technology Solutions Corporation
Oracle Corporation
PAREXEL International Corporation
PerkinElmer Inc.
SAS Institute Inc.
UnitedHealth Group Incorporated
Flatiron Health
Scope of the Report:
RWE Oncology Solutions Market, by Component
Real-world Datasets
Disparate Datasets
EMR/EHR/Clinical Data
Claims & Billing Data
Pharmacy Data
Cancer Registries
Other Disparate Datasets
Integrated Datasets
Real-world Consulting & Analytics Services
RWE Oncology Solutions Market, by Application
Drug Development & Approvals
Market Access & Reimbursement/Coverage Decisions
Post-market Surveillance
Medical Device Development & Approvals
Other Applications
RWE Oncology Solutions Market, by End User
Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users
RWE Oncology Solutions Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
South Korea
Taiwan
Singapore
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/1ktt5j
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900